Patents Examined by Timothy R Rozof
  • Patent number: 11826355
    Abstract: Pharmaceutical compositions comprising antioxidant drugs in the form of eye drops for treatment of age-related cataract, and methods thereof, are disclosed.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: November 28, 2023
    Inventor: Yansong Lu
  • Patent number: 11826356
    Abstract: The present application provides methods and compositions for treating diseases related to hematopoietic dysfunction and/or injury, by attenuating the expression and/or function of SphK2.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 28, 2023
    Assignee: Sun Yat-Sen University
    Inventor: Meng Zhao
  • Patent number: 11826340
    Abstract: The present invention provides use of a compound represented by formula (1), and the use is manufacturing a medicine for treating or preventing ischemic optic neuropathy, wherein the formula (1) is as below:
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: November 28, 2023
    Assignee: TZU CHI UNIVERSITY
    Inventors: Yu-Yau Chou, Jia-Ying Chien, Jhih-Wei Ciou, Shun-Ping Huang
  • Patent number: 11827580
    Abstract: Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (M-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
    Type: Grant
    Filed: December 27, 2022
    Date of Patent: November 28, 2023
    Assignee: ATAI Life Sciences AG
    Inventors: Glenn Short, Robert B. Perni, Tanweer A. Khan
  • Patent number: 11827603
    Abstract: The object of the present invention is to provide 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine having a low content of impurities The object can be solved by a method for preparing 1-(1-benzyl-4-piperidylacetyl)-4-hydroxypiperidine, comprising the steps of: (1) reductively reacting 1-benzyl-4-piperidylidene acetic acid ethyl ester represented by the formula [1]: to obtain 1-benzyl-4-piperidyl acetic acid ethyl ester represented by the formula [2]: (2) adding an ammonium chloride aqueous solution and an organic solvent to the liquid containing 1-benzyl-4-piperidyl acetic acid ethyl ester, mixing the whole, and separating into an organic layer and an aqueous layer, (3) collecting 1-benzyl-4-piperidyl acetic acid ethyl ester from the organic layer, and (4) reacting the obtained 1-benzyl-4-piperidyl acetic acid ethyl ester with 4-hydroxypiperidine represented by the formula [3]: in the presence of base, to obtain 1-(1-benzyl-4-piperidylacetyl)-4-hydroxypiperidine repr
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: November 28, 2023
    Assignee: YUKI GOSEI KOGYO CO., LTD.
    Inventors: Kiyono Nakagawa, Yoshihiro Ito, Hirohisa Kitahara
  • Patent number: 11820764
    Abstract: The present invention provides a novel compound of formula I, its derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for modulating GSK3 level (e.g., GSK3 (e.g., GSK3a/GSK3b or GSK3P) or CK1) hence, activity.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: November 21, 2023
    Assignee: National Institute of Immunology
    Inventors: Sarika Gupta, Ibrar Ahmed Siddiqui, Aishwarya Nilakhe, Prabhat Upadhyay
  • Patent number: 11820749
    Abstract: In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: November 21, 2023
    Assignees: The Regents of the University of California, Oak Ridge National Laboratory
    Inventors: Zoran Radic, Carlo Ballatore, Lukas Gorecki, Palmer Taylor, Andrey Kovalevsky, Xiaolin Cheng
  • Patent number: 11814354
    Abstract: The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: November 14, 2023
    Assignee: River 3 Renal Corp.
    Inventors: He Hongyan, Jiang Siyi, Urs Schwitter, Pascal Jean Claude Dott, Ralph Diodone, Nicole Wyttenbach, Olaf Grassmann
  • Patent number: 11814356
    Abstract: Provided is a cabozantinib acesulfamate salt and a crystalline form thereof. Also provided are pharmaceutical compositions including the salt and crystalline form thereof, and methods of treatment of progressive, metastatic medullary thyroid cancer (MTC) or advanced renal cell carcinoma (RCC) that has been treated previously with anti-angiogenic therapy using the cabozantinib acesulfamate salt.
    Type: Grant
    Filed: March 29, 2023
    Date of Patent: November 14, 2023
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Alexander J. Stirk, Avedis Karadeolian, Allan W. Rey
  • Patent number: 11807636
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: November 7, 2023
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • Patent number: 11801238
    Abstract: Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: October 31, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventor: Daniel L. Flynn
  • Patent number: 11801247
    Abstract: Methods of treating trypanosomiasis and, particularly, to methods of treating trypanosomiasis using raltitrexed. Such methods of treatment are useful in, for example, animals selected from the group consisting of cattle, sheep, pigs, goats, horses, and camels.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: October 31, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventor: Mahmoud Kandeel
  • Patent number: 11786602
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: October 17, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • Patent number: 11787820
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: October 17, 2023
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Patent number: 11786503
    Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: October 17, 2023
    Assignees: Auransa Inc., SCT II LLC
    Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
  • Patent number: 11787765
    Abstract: Disclosed are compounds of Formula 1, N-oxides of the compounds and salts of the compounds and N-oxides: wherein R1, R2, R3, R4, R5, R6, Q1, Q2, J, Y1, and Y2 are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxides and salts, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of such a compound, N-oxide, salt or composition.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: October 17, 2023
    Assignee: FMC Corporation
    Inventors: Andrew Duncan Satterfield, Matthew James Campbell, James Francis Bereznak, William Guy Whittingham, Glynn Mitchell, Christopher John Mathews, James Nicholas Scutt, James Alan Morris, Jonathan Wesley Paul Dallimore
  • Patent number: 11787766
    Abstract: Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-L1.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 17, 2023
    Assignee: SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD.
    Inventors: Lei Jiang, Jianwen Deng, Xiaoli Lu, Ke Shang, Jianyong Shou, Bing Wang, Danyi Wu, Xueli Xu, Yuan Xu, Yi Zhang, Mingwei Zheng
  • Patent number: 11780814
    Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: October 10, 2023
    Assignee: AlonBio Ltd.
    Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
  • Patent number: 11780813
    Abstract: The present invention provides a new production method for a chlorobenzene compound. Specifically, the present invention provides a production method in which the compound represented by formula (1) (in the formula, X1 represents a halogen atom) and chlorine are reacted in the presence of a Brønsted acid, thereby obtaining the chlorobenzene compound represented by formula (2) (in the formula, X1 represents the same as above).
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 10, 2023
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Junichi Ishikawa, Tohru Inoue, Takayuki Wakamatsu, Miyuki Iguchi
  • Patent number: 11773108
    Abstract: Compounds of formula (1): wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: October 3, 2023
    Assignee: Taro Pharmaceuticals Inc.
    Inventors: Curtis Harwig, Jeremy D. Pettigrew, Jennifer Cross, Jeyaprakashnarayanan Seenisamy, Mahesh Narayan Keregadde, Karthikeyan Iyanar